Skip to content
Menu

Oppenheimer Maintains Outperform on Kyntra Bio, Lowers Price Target to $30

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Jay Olson maintains Kyntra Bio (NASDAQ:KYNB) with a Outperform and lowers the price target from $35 to $30.

Oppenheimer analyst Jay Olson maintains Kyntra Bio (NASDAQ:KYNB) with a Outperform and lowers the price target from $35 to $30.

Read at benzinga.com